Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.

Authors	Ahmad H Ali, Cynthia W Buness, Ryan Fischer, Gerald J Holtmann, Ayesha Shah, Peter Lewindon, Shamita Shah, Amol S Ragnekar, Amy E Taylor, Aparna Goel, Kenneth L Cox, Leina Alrabadi, Steve Wadsworth, Sakil S Kulkarni, Keith D Lindor
Journal	Hepatology (Baltimore, Md.) (Hepatology) Vol. 77 Issue 6 Pg. E174-E175 (06 01 2023) ISSN: 1527-3350 [Electronic] United States
PMID	36705026 (Publication Type: Journal Article, Comment)
Chemical References	Vancomycin Anti-Bacterial Agents
Topics	Humans Vancomycin (therapeutic use) Cholangitis, Sclerosing (drug therapy) Anti-Bacterial Agents (therapeutic use) Insurance

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!